Prevalence, Clinical Significance, and Genetic Basis of Hypertrophic Cardiomyopathy With Restrictive Phenotype
Toru Kubo, MD*, ,
Juan R. Gimeno, MD*,
Ajay Bahl, MD*,
Ulla Steffensen*,
Morten Steffensen*,
Eyman Osman, BSc*,
Rajesh Thaman, MD*,
Jens Mogensen, MD, PhD*, ,
Perry M. Elliott, MD, FACC*,
Yoshinori Doi, MD, FACC and
William J. McKenna, MD, FACC*,*
* Department of Medicine, University College London, London, United Kingdom
Department of Medicine and Geriatrics, Kochi Medical School, Kochi, Japan
Department of Cardiology, Skejby University Hospital, Aarhus, Denmark. This study was supported by a grant from the British Heart Foundation
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Changes in Rhythm Status in Patients With HCM With Restrictive Phenotype
The figure shows changes in rhythm status from the initial clinical evaluation to the last recent clinical evaluation in 19 patients with hypertrophic cardiomyopathy (HCM) with "restrictive phenotype." AF = atrial fibrillation; PAF = paroxysmal atrial fibrillation.
|
|
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Kaplan-Meier Curves for HCM With Restrictive Phenotype Versus Other HCM
(A) Occurrence of all-cause mortality, cardiac transplantation, or implantable cardioverter-defibrillator discharge during follow-up. Log-rank for trend p = 0.008. (B) Occurrence of cardiovascular death, including death from cardiac transplantation and implantable cardioverter-defibrillator discharge, during follow-up. Log-rank for trend p = 0.001. (C) Occurrence of heart failure death and cardiac transplantation during follow-up. Log-rank for trend p < 0.0001. Thin lines = restrictive phenotype; thick lines = other hypertrophic cardiomyopathy (HCM).
|
|
|
